On the heels of competitor Madrigal’s excellent trial results another small BioPharma company has released phase 2 results that sent their company stock skyrocketing. Galmed Pharmaceuticals, a small Israeli biopharmaceutical company, produced statistically significant results with a drug called Aramchol in the lowering of fat in the liver at 52 weeks. The analysis of the results was embraced by the markets, which sent the stock soaring 250%.
In one endpoint, more patients treated with 600 mg of Aramchol versus placebo achieved NASH resolution without worsening of fibrosis, at 16.7% versus 5.0% (p=0.0514), respectively, as well as NASH resolution more generally, at 19.2% compared to 7.5% (p=0.0462). In addition, the second biopsy endpoint showed a higher proportion of patients with at least a one-point improvement in fibrosis score without worsening of NASH.
We are at an exciting time for NASH treatment options with multiple companies pursuing promising candidates. People suffering from NASH will still require significant lifestyle changes but hearing about more successful trial results is a very positive step towards getting a grip on the pandemic.
One thought on “Another promising NASH trial result from Galmed”
that was small study and it is unclear if 1 pont fibrosis improvement was for patients with f2-f4 fibrosis. and stock is down 800% from that news event.